Navigation Links
Vaxart Begins First Oral Vaccine Clinical Trial
Date:6/7/2011

SAN FRANCISCO, June 7, 2011 /PRNewswire/ -- Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has begun dosing volunteers in a Phase I clinical trial. This is the first clinical study evaluating a vaccine that uses the company's novel oral-vaccine platform technology. The trial site is in the United States.

"This first trial in humans is important, because if safety is demonstrated with one vaccine, we can expect that later vaccines using the same Vaxart technology will also be safe," said Vaxart founder and CSO Sean Tucker, Ph.D.

Vaxart's first oral vaccine candidate is designed to protect against H5N1 Avian Influenza. The company also has a pipeline of additional vaccines in development, all based on its oral-delivery technology.

Vaxart also announced the issuance of U.S. patent no. 7,879,602, which provides broad protection for the company's oral-delivery technology. "This patent greatly increases the value of our portfolio because it covers all methods we know of for oral vaccination with a re-usable platform technology," said Vaxart CEO Michael Finney, Ph.D.

About Vaxart TechnologyVaxart leverages proprietary vaccine development and formulation approaches to quickly and efficiently produce oral-delivery vaccines. Central to the company's approach is the incorporation of a unique adjuvant, the vaccine component that enhances immune responses, in the vector that delivers the vaccine antigen. Vaxart's adjuvant works by binding to Toll-Like Receptor 3 to stimulate a potent immune response when the vaccine is taken orally.

Vaxart's technology also enables all of the company's vaccines to use the same vector, or delivery vehicle. Until now, each time an individual received a vector vaccine, a new vector needed to be used. This is because after receiving a vector vaccine, people develop antibodies to the vector itself, and these anti-vector antibodies reduce the effectiveness of later vaccin
'/>"/>

SOURCE Vaxart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
2. Vaxart Begins Animal Testing of H1N1 Flu Vaccine Candidate
3. GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season
4. Cellectar, Inc. Begins GMP Production
5. South Africa Begins Introduction of PREVENAR into Childhood Immunization Program
6. Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins
7. The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
8. Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
9. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
10. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
11. SemBioSys begins phase I/II trial of insulin produced in plant seeds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... OR and Hershey, PA (PRWEB) December 19, 2014 ... Pink: BJCT), a leading developer and manufacturer of ... entered into an agreement with Immunomic Therapeutics, Inc. ... Biojector®-2000 needle-free injection device with its LAMP™ vaccine ... an option for an exclusive Worldwide license to ...
(Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ROG; ... Technologies, Inc. (Bina), a privately held company based ... USA. Bina provides a big data platform for ... (NGS) data. Bina,s proprietary on-market Genomic Management Solution, ... researchers to perform fast and scalable analyses to ...
(Date:12/19/2014)... 19, 2014 Decision Resources Group finds that ... a 12 percent compound annual growth rate through 2023. ... population and the increasing adoption of dental implants. Growing ... will also spur demand for dental biomaterials because they ... periodontal treatments. Other key findings from Decision ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... , , ... Q4 and full-year results today with CEO David,Brennan saying ... restructuring had helped deliver a revenue line above company,expectations. , ... results and the drivers behind a 23%,rise in core operating profit ...
... ... that allows researchers to build nano-sized structures out of DNA (or RNA). To help illustrate ... allows users to build virtual nanostructures by sequencing a simple, abstract representation of a DNA ... ...
... , , SAO PAULO , ... Commission to propose additional out-of-quota sugar exports for an,amount of ... on the Commission for a cautious approach, taking into,consideration all ... According to UNICA, the European Commission is sending ...
Cached Biology Technology:AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009 2Wyss Institute Launches "Molecular Origami" Interactive Feature 2Wyss Institute Launches "Molecular Origami" Interactive Feature 3Cautious Approach Needed Before Any Decision on EU Out-of-Quota Sugar Exports Is Taken 2
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
(Date:12/5/2014)... Dec. 4, 2014 Increased emphasis on ... in new testing and inspection technologies. The convergence ... to a range of innovative test solutions. This ... Generation Y, which is generally more inclined towards ... product development strategies of test equipment vendors will ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... ear of a tropical butterfly that potentially makes it able ... discovered by scientists from the University of Bristol, UK. ... associated with the detection of predators, in particular birds. ... Central and South America, are more famous for their amazing ...
... knee joints might one day be repaired with cartilage grown ... Professor Kyriacos Athanasiou, chair of the UC Davis Department of ... from bone marrow and skin as well as human embryonic ... tissue in the lab. Now they are experimenting with various ...
... were the key to the end of the dinosaurs, ... and ecotoxicologist John H. Rodgers have published findings that ... extinctions millions of years ago. The research not only ... a caution about the future. The scientists say that ...
Cached Biology News:Clemson researchers say algae key to mass extinctionss 2
All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
adult...
DNA Purification...
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Biology Products: